Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

Cytokinetics Incorporated (CYTK)

NASDAQ: CYTK · Pharmaceutical Preparations · South San Francisco, CA

Our rating: Positive

Call changed from Cautious to Positive at $55.55, moderate conviction, November 5, 2026.

Breaks if: The Positive view rests on the commercial revenue ramp sustaining momentum. It would be proved wrong if revenue growth decelerates to below 80% year-over-year in either of the next two quarterly reports — a level that would signal the launch is losing steam well before the revenue base can support the valuation — or if the annualized FCF burn rate rises above $700 million for any single reported quarter within the next twelve months, implying cost escalation has outrun the top line. Either condition would call the duration of the runway into serious question and shift the balance of evidence toward Cautious.

Key figures

Market value$7.1B
Revenue, last 12 months$113M
Net income, last 12 months−$778M
Free cash flow, last 12 months−$589M
Price to earningsn/a
Free cash flow yield−8.3%
Dividend yield0.0%
Operating margin−625.2%
Return on equityn/a
Beta to the S&P 5000.83
Volatility, annualized53.7%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026$48M2356.5%$-1.37−$125M
June 30, 2026$29M−57.1%$-1.50−$164M
March 31, 2026$19M1125.8%$-1.67−$151M
December 31, 2025$18M4.9%$-1.50−$148M
September 30, 2025$2M318.1%$-2.55−$117M
June 30, 2025$67M26714.9%$-1.12−$132M
March 31, 2025$2M89.1%$-1.36−$137M
December 31, 2024$17M912.4%$-1.26−$67M

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

16 ledger entries and 28 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.